Sistēmiski lietojamo hormonālās kontracepcijas līdzekļu lietošanas drošuma analīze
No Thumbnail Available
Date
2022
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Rīgas Stradiņa universitāte
Rīga Stradiņš University
Rīga Stradiņš University
Abstract
Tirgū ir pieejami sistēmiski lietojamie kontracepcijas līdzekļi (SLKL), kas satur
estrogēna un progestīna kombināciju, vai tikai progestīnu. Sievietēm hormonālās
kontracepcijas tabletes tiek nozīmētās dažādu iemeslu dēļ – piemēram, lai pasargātu organismu
no nevēlamās grūtniecības iestāšanos vai lai veicinātu sievietes organisma veselību. Pirms ārsts
nozīmē konkrēto SLKL, viņam būtu jāizmeklē pacients, analizējot vecumu un ķermeņa masas
indeksu (ĶMI), iemeslus uzsākt hormonālo terapiju un konstatēt vēlamo efektu no terapijas
lietošanas, ņemt vērā pacientu hroniskas slimības un zāļu lietošanas pieredzi, kā arī pacienta
īpatnības riska faktoru kontekstā.
Pētnieciskā darba tēma ir "Sistēmiski lietojamo hormonālās kontracepcijas līdzekļu
lietošanas drošuma analīze". Pētījuma mērķis bija izanalizēt iegūto informāciju par sieviešu
lietotiem SLKL un novērotām blakusparādībām, lai atrastu saistības ar potenciāliem riska
faktoriem un izdarītu aktuālos sacinājumus par situāciju mūsdienās. Pētījumā tika noskaidrots,
ka pastāv statistiski nozīmīgas atšķirības starp konkrētām novērotām blakusparādībām un
noteiktā ķīmiskā sastāva SLKL lietošanu, kā arī nozīme ir veselības pārbaudei pirms
hormonālās terapijas uzsākšanas un SLKL regulārai lietošanai pēc ārsta norādījumiem. Ar
pareizo pieeju hormonālajai terapijai var izvairīties no SLKL terapijas maiņas vai atteikšanas
novēroto blakusparādību dēļ.
Systemic hormonal contraceptives (SHC) which are available on the market contains a combination of estrogen and progestin, or progestin only. Hormonal contraceptive pills are prescribed for women for a variety of reasons, such as body protection from an unwanted pregnancy or woman's health promotion. The physician should examine the patient before prescribing a specific SHC – should check the woman's age and body mass index (BMI), determine reasons for initiating hormonal therapy and the desired effect of the treatment, taking into account the patient's chronic diseases and medication using experience, and the patient's characteristics in the context of risk factors. The topic of the research is "Safety analysis of using systemic hormonal contraceptives". The aim of the study was to analyze the obtained information about using of SHC and observed side effects in women, in order to find links with potential risk factors and to make statements about the current situation. The study found that there were statistically significant differences between the observed specific side effects and using of the prescribed chemical composition of SHC, as well as it is very important to make health screenings before using hormonal therapy and to use SHC regularly as directed by a physician. With the right approach to hormonal therapy, it is possible to avoid the SHC therapy changing or canceling because of adverse effects.
Systemic hormonal contraceptives (SHC) which are available on the market contains a combination of estrogen and progestin, or progestin only. Hormonal contraceptive pills are prescribed for women for a variety of reasons, such as body protection from an unwanted pregnancy or woman's health promotion. The physician should examine the patient before prescribing a specific SHC – should check the woman's age and body mass index (BMI), determine reasons for initiating hormonal therapy and the desired effect of the treatment, taking into account the patient's chronic diseases and medication using experience, and the patient's characteristics in the context of risk factors. The topic of the research is "Safety analysis of using systemic hormonal contraceptives". The aim of the study was to analyze the obtained information about using of SHC and observed side effects in women, in order to find links with potential risk factors and to make statements about the current situation. The study found that there were statistically significant differences between the observed specific side effects and using of the prescribed chemical composition of SHC, as well as it is very important to make health screenings before using hormonal therapy and to use SHC regularly as directed by a physician. With the right approach to hormonal therapy, it is possible to avoid the SHC therapy changing or canceling because of adverse effects.
Description
Farmācija
Pharmacy
Veselības aprūpe
Health Care
Pharmacy
Veselības aprūpe
Health Care
Keywords
SLKL, KOK, OK, estrogēns, estradiols, etinilestradiols, progesterons, hlormadinona acetāts, dienogests, dezogestrels, drospirenons, gestodens, levonorgestrels, riski, blakusparādības, riski, polifarmācija, mijiedarbības, SHC, COC, OC, estrogen, estradiol, ethinylestradiol, progesteron, chlormadinone
acetate, dienogest, desogestrel, drospirenone, gestodene, levonorgestrel, risks, adverse effects, risks, polypharmacy, interactions